Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 685-692

  Li, Juan ^a   Li, Ping ^a   Chen, Tengfei ^a   Gao, Ge ^b   Chen, Xiaonan ^b   Du, Yuwen ^b   Zhang, Ren ^b   Yang, Rui ^a   Zhao, Wei ^a   Dun, Shaozhi ^a   Gao, Feng ^a   Zhang, Guojun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; FOXO3; Invasion; miR 96; NSCLC; Proliferation

Indexed keywords

MICRORNA; MICRORNA 96; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MIRN96 MICRORNA, HUMAN; TUMOR MARKER;

A549 CELL LINE; ADULT; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL COUNTING; CELL INVASION; CELL SURVIVAL; COMPARATIVE STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MALE; METASTASIS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925502031     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2698-y     Document Type: Article

References (52)

1. Jemal A, Center MM, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.
2. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91–112.
3. Favaretto AG, Pasello G, Magro C. Second and third line treatment in advanced non-small cell lung cancer. Discov Med. 2009;8(43):204–9.
4. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–16.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
6. Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.
7. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353:1768–71.
8. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–14.
9. Garzon R, Marcucci G. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 2012;24:655–9.
10. Hoshino I, Matsubara H. MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today. 2013;43:467–78.
11. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012;16:747–59.
12. Jones CI, Zabolotskaya MV, Newbury SF, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107:1987–96.
13. Zhang X, Zeng J, Chen C, et al. The tumor suppressive role of miRNA-370 by targeting FOXM1 in acute myeloid leukemia. Mol Cancer. 2012;11:56.
14. Ma L, Huang Y, Zhu W, Jun Y, et al. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. 2011;6(10):e26502.
15. Lin H, Dai T, Chen X, et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 2011;5:e15797.
16. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204–16.
17. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24:7410–25.
18. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120:2479–87.
19. Hu MC, Lee DF, Ou-Yang F, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004;117:225–37.
20. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005;65:3509–12.
21. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;857–66.
22. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.
23. Bandrés E, Cubedo E, Zárate R, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;29:1–10.
24. Pineau P, Volinia S, Battiston C, et al. MiR-221 over-expression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264–9.
25. Han Y, Chen J, Wang Y, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011;6:e18286.
26. Schaefer A, Jung M, Stephan C, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166–76.
27. Agirre X, Jiménez-Velasco A, Bandrés E, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6:1830–40.
28. Zhu W, Liu X, Hunag Y, et al. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011;11:393.
29. Ozsolak F, Poling LL, Fisher DE, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008;22:3172–83.
30. Myatt SS, Wang J, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2010;70:367–77.
31. Jalvy-Delvaille S, Maurel M, Chabas S, et al. Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res. 2012;40:1356–65.
32. Yang JY, Zong CS, Ding QQ, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MCM2-mediated degradation. Nat Cell Biol. 2008;10:370.
33. Paik JH, Kollipara R, DePinho RA, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128(2):309–23.
34. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7(11):847–59.
35. Alvarez B. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature. 2001;413:744–7.
36. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004;306:2105–8.
37. Tran H. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science. 2002;296:530–4.
38. Tsai WB. Functional interaction between FOXO3 and ATM regulates DNA damage response. Nat Cell Biol. 2008;10:460–7.
39. Furukawa-Hibi Y. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal. 2005;7:752–60.
40. Willcox BJ. FOXO3a genotype is strongly associated with human longevity. Proc Natl Acad Sci U S A. 2008;105:13987–92.
41. Brunet A. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–68.
42. Sunters A. FOXO3 transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003;278:49795–805.
43. Yang JY. Induction of FOXO3a and Bim expression in response to ionizing radiation. Int J Oncol. 2006;29:643–8.
44. Hu MC. IκB kinase promotes tumourigenesis through inhibition of Forkhead FOXO3. Cell. 2004;117:225–37.
45. Seoane J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004;117:211–23.
46. Habashy HO. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat. 2011;129:11–21.
47. Jiang Y. Foxo3a expression is a prognostic marker in breast cancer. PLoS One. 2013;8:e70746.
48. Paik JH. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128:309–23.
49. Miyamoto K. FOXO3 is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell. 2007;1:101–12.
50. Fei M. Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest. 2009;27:52–9.
51. Yang XB, Zhao JJ, Pan K, et al. Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients. PLoS One. 2013;8(10):e78158.
52. Shukla S, Shukla M, Gupta S, et al. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol. 2009;34:1613–20.